Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizum...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatrics (Evanston) Vol. 125; no. 1; p. e35
Main Authors:	Carbonell-Estrany, Xavier, Simões, Eric A F, Dagan, Ron, Hall, Caroline B, Harris, Brian, Hultquist, Micki, Connor, Edward M, Losonsky, Genevieve A
Format:	Journal Article
Language:	English
Published:	United States 01.01.2010
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Child, Preschool Confidence Intervals Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Infant, Premature Kaplan-Meier Estimate Male Palivizumab Primary Prevention - methods Probability Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - mortality Respiratory Syncytial Virus Infections - prevention & control Risk Assessment Survival Rate Treatment Outcome
ISSN:	1098-4275, 1098-4275
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!